Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mitsubishi Tanabe Pharma Corporation

http://www.mt-pharma.co.jp/e/index.php

Latest From Mitsubishi Tanabe Pharma Corporation

Finance Watch: Perlmutter’s Eikon Raises $106m, In-Licenses Pipeline Programs

Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.

Financing Deals

Finance Watch: Mega-Round Mania As RNA Therapeutics, Gene Editing Attract VC Cash

Private Company Edition: Two companies raised multiple hundreds of millions of dollars each helping to keep the number of $100m-plus venture capital mega-rounds on the rise in May. Also, Ascend raised $132.5m to make gene and cell therapies, and Nido emerged with $109m for neurological diseases.

Financing Innovation

Supplemental Filings: Back To US FDA’s Conference Center, What Marks Wants In A Gene Therapy Director, And More

Short stories about how US FDA’s conference center changed since COVID-19 forced the end of in-person public events, what the agency did to officially close the books on Makena, and more.

FDA Gene Therapy

Unvalidated PROs In Rare Diseases: US FDA May Have To ‘Work Through’ Them, CBER’s Marks Says

Given the challenges of validating patient-reported outcome instruments specific to very rare diseases, agency is probably going to have to accept the use of unvalidated measures in some cases, Peter Marks tells American Society of Gene and Cell Therapy’s annual meeting.

Rare Diseases Gene Therapy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Nutraceuticals
    • OTC, Consumer
    • Vaccines
  • Biotechnology
    • Drug Discovery Technologies
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • BIXEN Corporation
    • Medicago Inc.
    • Mitsubishi Tanabe Pharma America, Inc. (MTPA)
    • Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA)
    • Mitsubishi Tanabe Pharma Singapore Pte. Ltd.
    • NeuroDerm, Ltd. (NDRM)
    • PT Mitsubishi Tanabe Pharma Indonesia
    • Mitsubishi Tanabe Pharma (Thailand)
    • MT Pharma Singapore PTE. Ltd.
    • Tai Tien Pharmaceuticals Co., Ltd.
    • Tanabe Research Laboratories U.S.A.
UsernamePublicRestriction

Register